Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Federica Matteucci

Showing results (41-50 of 80) with videos related to

Pageof 8
Sort By:
European Journal of Nuclear Medicine and Molecular Imaging|November 8, 2017
Prognostic value of 18F-choline PET/CT metabolic parameters in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamidePaola Caroli, Ugo De Giorgi, Emanuela Scarpi, et al.
Frontiers in Oncology|July 12, 2021
Exploratory Analysis of <sup>18</sup>F-3'-deoxy-3'-fluorothymidine (<sup>18</sup>F-FLT) PET/CT-Based Radiomics for the Early Evaluation of Response to Neoadjuvant Chemotherapy in Patients With Locally Advanced Breast CancerLorenzo Fantini, Maria Luisa Belli, Irene Azzali, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 27, 2015
(18)F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamideUgo De Giorgi, Paola Caroli, Emanuela Scarpi, et al.
Biomedicines|March 28, 2026
Prostate-Specific Membrane Antigen (PSMA): A Potential Theranostic Biomarker in Breast CancerAlessandra Virga, Flavia Foca, Stefania Cortecchia, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 23, 2015
Erratum to: (18)F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamideUgo De Giorgi, Paola Caroli, Emanuela Scarpi, et al.
Molecular Oncology|October 17, 2021
Combining liquid biopsy and functional imaging analysis in metastatic castration-resistant prostate cancer helps predict treatment outcomeVincenza Conteduca, Emanuela Scarpi, Paola Caroli, et al.
Biomedicines|December 1, 2020
<sup>68</sup>Ga-PSMA-11 PET/CT-Guided Stereotactic Body Radiation Therapy Retreatment in Prostate Cancer Patients with PSA Failure after Salvage RadiotherapyPaola Caroli, Sarah Pia Colangione, Ugo De Giorgi, et al.
Cancers|December 23, 2022
<sup>177</sup>Lu-DOTATATE Efficacy and Safety in Functioning Neuroendocrine Tumors: A Joint Analysis of Phase II Prospective Clinical TrialsAlberto Bongiovanni, Silvia Nicolini, Toni Ibrahim, et al.
Frontiers in Oncology|January 21, 2026
Toward a PSMA PET-mpMRI pathway for biopsy decision-making in men with suspected prostate cancer: interim results from the prospective BIOPSTAGE trialMonica Celli, Roberta Gunelli, Fabio Ferroni, et al.
Nuclear Medicine Communications|October 17, 2014
111In-Pentetreotide (OctreoScan) scintigraphy in the staging of small-cell lung cancer: its accuracy and prognostic significanceGiovenzio Genestreti, Alberto Bongiovanni, Marco Angelo Burgio, et al.
Pageof 8

Showing results (41-50 of 80) with videos related to

Sort By:
Pageof 8
European Journal of Nuclear Medicine and Molecular Imaging|November 8, 2017
Prognostic value of 18F-choline PET/CT metabolic parameters in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamidePaola Caroli, Ugo De Giorgi, Emanuela Scarpi, et al.
Frontiers in Oncology|July 12, 2021
Exploratory Analysis of <sup>18</sup>F-3'-deoxy-3'-fluorothymidine (<sup>18</sup>F-FLT) PET/CT-Based Radiomics for the Early Evaluation of Response to Neoadjuvant Chemotherapy in Patients With Locally Advanced Breast CancerLorenzo Fantini, Maria Luisa Belli, Irene Azzali, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 27, 2015
(18)F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamideUgo De Giorgi, Paola Caroli, Emanuela Scarpi, et al.
Biomedicines|March 28, 2026
Prostate-Specific Membrane Antigen (PSMA): A Potential Theranostic Biomarker in Breast CancerAlessandra Virga, Flavia Foca, Stefania Cortecchia, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 23, 2015
Erratum to: (18)F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamideUgo De Giorgi, Paola Caroli, Emanuela Scarpi, et al.
Molecular Oncology|October 17, 2021
Combining liquid biopsy and functional imaging analysis in metastatic castration-resistant prostate cancer helps predict treatment outcomeVincenza Conteduca, Emanuela Scarpi, Paola Caroli, et al.
Biomedicines|December 1, 2020
<sup>68</sup>Ga-PSMA-11 PET/CT-Guided Stereotactic Body Radiation Therapy Retreatment in Prostate Cancer Patients with PSA Failure after Salvage RadiotherapyPaola Caroli, Sarah Pia Colangione, Ugo De Giorgi, et al.
Cancers|December 23, 2022
<sup>177</sup>Lu-DOTATATE Efficacy and Safety in Functioning Neuroendocrine Tumors: A Joint Analysis of Phase II Prospective Clinical TrialsAlberto Bongiovanni, Silvia Nicolini, Toni Ibrahim, et al.
Frontiers in Oncology|January 21, 2026
Toward a PSMA PET-mpMRI pathway for biopsy decision-making in men with suspected prostate cancer: interim results from the prospective BIOPSTAGE trialMonica Celli, Roberta Gunelli, Fabio Ferroni, et al.
Nuclear Medicine Communications|October 17, 2014
111In-Pentetreotide (OctreoScan) scintigraphy in the staging of small-cell lung cancer: its accuracy and prognostic significanceGiovenzio Genestreti, Alberto Bongiovanni, Marco Angelo Burgio, et al.
Pageof 8